Pdt Partners, LLC Viking Therapeutics, Inc. Transaction History

Pdt Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $90,476 - $138,021	-35,481 Reduced 43.14%	46,758 $127,000
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $162,228 - $263,890	-54,076 Reduced 39.67%	82,239 $247,000
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $148,911 - $217,539	32,372 Added 31.14%	136,315 $627,000
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $185,814 - $234,432	-33,300 Reduced 24.26%	103,943 $653,000
Q2 2021 Aug 16, 2021	BUY	$5.19 - $6.73 $492,780 - $639,000	94,948 Added 224.49%	137,243 $822,000
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $242,773 - $408,992	42,295 New	42,295 $268,000
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $255,958 - $324,052	-48,294 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.73 - $8.11 $276,724 - $391,664	48,294 New	48,294 $281,000
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $111,535 - $257,015	-32,329 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.38 - $8.73 $206,259 - $282,232	32,329 New	32,329 $259,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.